FDA Approved: AMONDYS 45 — Supplemental Application (Sarepta Therapeutics, Inc.)

View source ↗

Summary

FDA approved a supplemental application for Amondys 45 (casimersen) from Sarepta Therapeutics, Inc., related to Duchenne muscular dystrophy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• AMONDYS 45 (Casimersen)

Snippet

SUPPL AP for AMONDYS 45 (CASIMERSEN)